BCL2A1 and lung cancer: Figure 1 and Figure Additional file 1, Figure S1 showed that low dose gemcitabine activated NF-κB and up-regulated Bfl-1 expression in lung cancer cells, which might be one of the underlying resistant mechanisms to low dose gemcitabine.